| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
The molecular targets of Nezukone are not fully elucidated, but the compound is primarily studied as a bioactive organic compound with anti-inflammatory, antioxidant, and neuroprotective properties. Structurally, Nezukone contains a tropone backbone and is an analogue of hinokitiol. Unlike hinokitiol, Nezukone cannot bind or transport iron. Studies suggest that Nezukone can inhibit pro-inflammatory mediators and scavenge reactive oxygen species. The compound is primarily used in pharmacological research exploring natural products for therapeutic applications in inflammation, neuroprotection, and vascular health. Its mechanism of action may involve modulation of inflammatory and oxidative stress pathways.
|
|---|---|
| ln Vitro |
Nezukone demonstrates notable in vitro pharmacological activities, including anti-inflammatory, antioxidant, and neuroprotective effects. Studies suggest that Nezukone can inhibit pro-inflammatory mediators and scavenge reactive oxygen species. As a derivative of hinokitiol, Nezukone shares structural similarities but lacks the iron-binding and -transporting activity of hinokitiol. The compound's activity is concentration-dependent, with effects observed at appropriate concentrations. Nezukone is used in pharmacological research exploring natural products for therapeutic applications in inflammation, neuroprotection, and vascular health. Comprehensive in vitro activity data have been reported in research publications.
|
| ln Vivo |
In vivo activity of Nezukone has been less extensively characterized compared to its in vitro activity. As a naturally occurring compound with anti-inflammatory, antioxidant, and neuroprotective properties, Nezukone would be expected to have potential therapeutic applications. However, comprehensive in vivo efficacy studies in animal models have not been extensively published. The compound is primarily used as a research tool for in vitro studies of inflammation, oxidative stress, and neuroprotection. Further research is needed to determine whether Nezukone's in vitro activities translate to in vivo efficacy.
|
| Enzyme Assay |
In vitro assays for Nezukone typically involve measuring its anti-inflammatory, antioxidant, and neuroprotective activities. Anti-inflammatory activity is assessed by measuring the inhibition of pro-inflammatory cytokine production (TNF-alpha, IL-1beta, IL-6) in LPS-stimulated macrophages or microglial cells. Antioxidant activity is assessed using DPPH or ABTS radical scavenging assays, or by measuring the inhibition of ROS production in cells treated with oxidative stress inducers. Neuroprotective activity is assessed in neuronal cell lines treated with neurotoxic agents in the presence or absence of the compound. Cell viability is measured using MTT or CellTiter-Glo assays. Each concentration is typically tested in duplicate or triplicate with appropriate positive controls (known anti-inflammatory or antioxidant compounds) and vehicle controls.
|
| Cell Assay |
In vitro cellular assays for Nezukone are performed using various cell lines depending on the biological activity being studied. For anti-inflammatory assays, macrophages (RAW264.7) or microglial cells (BV2) are stimulated with LPS and treated with varying concentrations of Nezukone. Cytokine production (TNF-alpha, IL-1beta, IL-6) is measured by ELISA. Nitric oxide production is measured using the Griess reagent. For antioxidant assays, cells are treated with oxidative stress inducers (H2O2 or rotenone) and Nezukone, and ROS production is measured using fluorescent probes such as DCFH-DA. For neuroprotective assays, neuronal cell lines (SH-SY5Y or PC12) are treated with neurotoxic agents (MPP+, glutamate, or Abeta) and Nezukone, and cell viability is assessed. Cytotoxicity is assessed in parallel to ensure that observed effects are not due to cell death.
|
| Animal Protocol |
In vivo animal studies for Nezukone have not been extensively reported in the public domain. As a naturally occurring compound with anti-inflammatory, antioxidant, and neuroprotective properties, Nezukone could potentially be evaluated in animal models of inflammation, oxidative stress, and neurodegenerative diseases. In such studies, the compound would be administered via oral gavage or intraperitoneal injection, and endpoints would include inflammatory markers, oxidative stress markers, and behavioral outcomes. However, comprehensive in vivo efficacy studies have not been widely published. The compound is primarily used as a research tool for in vitro studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Nezukone have not been extensively characterized in the public domain. The compound has a molecular formula of C10H12O and a molecular weight of 148.20 g/mol. Its IUPAC name is 4-propan-2-ylcyclohepta-2,4,6-trien-1-one. Nezukone is also known as C2-deoxyhinokitiol and 4-isopropyltropone. As a small, lipophilic molecule, Nezukone would be expected to have reasonable oral bioavailability. However, comprehensive pharmacokinetic parameters including half-life, volume of distribution, clearance, and oral bioavailability have not been reported.
|
| Toxicity/Toxicokinetics |
Nezukone is intended for laboratory research use only and has not undergone comprehensive toxicology testing. As a naturally occurring compound found in medicinal plants, Nezukone may have a favorable safety profile, but specific toxicity data have not been extensively reported. Standard in vitro cytotoxicity assays in cell lines are typically performed alongside efficacy studies to rule out nonspecific toxicity. In vivo, animals would be monitored for signs of toxicity if the compound were to be evaluated in animal studies. Comprehensive toxicological characterization including genotoxicity and repeated-dose toxicity studies has not been reported. The compound is not approved for human use and is strictly intended for research purposes.
|
| Additional Infomation |
According to reports, 2,4,6-cycloheptatrien-1-one, 4-isopropyl-, has been found in the ginger family plants Alpinia zerumbet and Etlingera elatior, and relevant data are available.
Nezukone (C2-deoxyhinokitiol, 4-isopropyltropone) is a naturally occurring tropone derivative and analogue of hinokitiol isolated from Angelica decursiva. It possesses anti-inflammatory, antioxidant, and neuroprotective activities. Unlike hinokitiol, Nezukone cannot bind or transport iron. The compound has a molecular formula of C10H12O and a molecular weight of 148.20 g/mol. Nezukone has not entered clinical trials and is available for research purposes only. |
| Molecular Formula |
C10H12O
|
|---|---|
| Molecular Weight |
148.2017
|
| Exact Mass |
148.089
|
| CAS # |
13656-81-0
|
| PubChem CID |
570867
|
| Appearance |
Light brown to brown oil
|
| LogP |
2.17
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
1
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
11
|
| Complexity |
242
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1C([H])=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])[H])C([H])([H])[H]
|
| InChi Key |
IWPWMAJDSLSRIP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C10H12O/c1-8(2)9-4-3-5-10(11)7-6-9/h3-8H,1-2H3
|
| Chemical Name |
4-propan-2-ylcyclohepta-2,4,6-trien-1-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ≥ 100 mg/mL (~674.76 mM)
Ethanol : ~100 mg/mL (~674.76 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 3.75 mg/mL (25.30 mM) (saturation unknown) in 10% DMSO + 40% PEG300 +5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 37.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 + to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 6.7476 mL | 33.7382 mL | 67.4764 mL | |
| 5 mM | 1.3495 mL | 6.7476 mL | 13.4953 mL | |
| 10 mM | 0.6748 mL | 3.3738 mL | 6.7476 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
